TMCnet - World's Largest Communications and Technology Community



Aptose to Present at BIO-Europe Conference
[November 07, 2019]

Aptose to Present at BIO-Europe Conference

SAN DIEGO and TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in the 25th Annual International BIO-Europe Partnering Conference, being held November 11th -13th in Hamburg, Germany. Aptose will be presenting and hosting 1x1 meetings.

25th Annual International BIO-Europe Partnering Conference
Presentation Date:Tuesday, November 12, 2019, 15:45 CET
Location:Hamburg Messe, Hamburg
 Level 0, B1, Room 4

About Aptose

Aptose Biosciencs is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit

For further information, please contact:

Aptose BiosciencesSMP Communications
Greg ChowSusan Pietropaolo
Senior Vice President, CFO201-923-2049 
LifeSci Advisors, LLC 
Daniel Ferry 
Managing Director 

Primary Logo

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy